Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment

References

• Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem. 2017;24(27):3002–3009. doi:10.2174/0929867324666170516123206.
   PubMed Web of Science ®Google Scholar
• Zanders ED, Svensson F, Bailey DS. Therapy for glioblastoma: is it working? Drug Discov Today. 2019;24(5):1193–1201. doi:10.1016/j.drudis.2019.03.008.
   PubMed Web of Science ®Google Scholar
• Merzak A, Pilkington GJ. Molecular and cellular pathology of intrinsic brain tumours. Cancer Metastasis Rev. 1997;16(1–2):155–77. doi:10.1023/A:1005760726850.
   PubMed Web of Science ®Google Scholar
• Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21(8):1624–1636. doi:10.1200/JCO.2003.05.063.
   PubMed Web of Science ®Google Scholar
• Reznik E, Smith AW, Taube S, Mann J, Yondorf MZ, Parashar B, Wernicke AG. Radiation and immunotherapy in high-grade gliomas: where do we stand? Am J Clin Oncol. 2018;41(2):197–212. doi:10.1097/COC.0000000000000406.
   PubMed Web of Science ®Google Scholar
• Sorribes IC, Handelman SK, Jain HV. Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition. J R Soc Interface. 2020;17(162):20190722. doi:10.1098/rsif.2019.0722.
   PubMed Web of Science ®Google Scholar
• Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir. 2018;58(10):405–421. doi:10.2176/nmc.ra.2018-0141.
   PubMed Web of Science ®Google Scholar
• Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. doi:10.1186/s13046-016-0303-5.
   PubMed Web of Science ®Google Scholar
• Vengoji R, Macha MA, Batra SK, Shonka NA. Natural products: a hope for glioblastoma patients. Oncotarget. 2018;9(31):22194–22219. doi:10.18632/oncotarget.25175.
   PubMedGoogle Scholar
• Valle-Folgueral JM, Mascarenhas L, Costa JA, Vieira F, Soares-Fernandes J, Beleza P, Alegria C. Giant cell glioblastoma: review of the literature and illustrated case. Neurocirugia. 2008;19(4):343–349. doi:10.1016/S1130-1473(08)70221-5.
   PubMed Web of Science ®Google Scholar
• Facchino S, Abdouh M, Bernier G. Brain cancer stem cells: current status on glioblastoma multiforme. Cancers. 2011;3(2):1777–1797. doi:10.3390/cancers3021777.
   PubMedGoogle Scholar
• Sorensen MD, Fosmark S, Hellwege S, Beier D, Kristensen BW, Beier CP. Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. Adv Exp Med Biol. 2015;853:111–138. doi:10.1007/978-3-319-16537-0_7.
   PubMed Web of Science ®Google Scholar
• Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501–513. doi:10.1016/j.ccr.2009.03.018.
   PubMed Web of Science ®Google Scholar
• Codrici E, Enciu AM, Popescu ID, Mihai S, Tanase C. Glioma stem cells and their microenvironments: providers of challenging therapeutic targets. Stem Cells Int. 2016;2016:5728438. doi:10.1155/2016/5728438.
   PubMed Web of Science ®Google Scholar
• Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8(20):3274–3284. doi:10.4161/cc.8.20.9701.
   PubMed Web of Science ®Google Scholar
• Hira VVV, Van Noorden CJF, Molenaar RJ. CXCR4 antagonists as stem cell mobilizers and therapy sensitizers for acute myeloid leukemia and glioblastoma? Biology. 2020;9(2):31. doi:10.3390/biology9020031.
   Google Scholar
• Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010;133(Pt 4):983–995. doi:10.1093/brain/awq042.
   PubMedGoogle Scholar
• Prager BC, Bhargava S, Mahadev V, Hubert CG, Rich JN. Glioblastoma stem cells: driving resilience through chaos. Trends Cancer. 2020;6(3):223–235. doi:10.1016/j.trecan.2020.01.009.
   PubMed Web of Science ®Google Scholar
• Sousa JF, Serafim RB, Freitas LM, Fontana CR, Valente V. DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance. Genet Mol Biol. 2019;43(1 suppl 1):e20190066. doi:10.1590/1678-4685-GMB-2019-0066.
   PubMed Web of Science ®Google Scholar
• Qiu ZK, Shen D, Chen YS, Yang QY, Guo CC, Feng BH, Chen ZP. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer. 2014;33(2):115–122. doi:10.5732/cjc.012.10236.
   PubMedGoogle Scholar
• Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, et al. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol. 2014;44(2):591–599. doi:10.3892/ijo.2013.2209.
   PubMed Web of Science ®Google Scholar
• Ahmed AU, Auffinger B, Lesniak MS. Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Rev Neurother. 2013;13(5):545–555. doi:10.1586/ern.13.42.
   PubMed Web of Science ®Google Scholar
• Chumakova A, Lathia JD. Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: an editorial highlight for ‘transcriptional control of O6-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma’ on page 780. J Neurochem. 2018;144(6):688–690. doi:10.1111/jnc.14280.
   PubMed Web of Science ®Google Scholar
• Santos-Barriopedro I, Li Y, Bahl S, Seto E. HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1. Genes Cancer. 2019;10(5–6):119–133. doi:10.18632/genesandcancer.197.
   PubMedGoogle Scholar
• Park J, Shim JK, Yoon SJ, Kim SH, Chang JH, Kang SG. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. Sci Rep. 2019;9(1):10555. doi:10.1038/s41598-019-47066-y.
   PubMedGoogle Scholar
• Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, Kaina B. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer. 2010;127(9):2106–2118. doi:10.1002/ijc.25229.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9(1):2949. doi:10.1038/s41467-018-05373-4.
   PubMedGoogle Scholar
• Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res. 2009;7(3):383–392. doi:10.1158/1541-7786.MCR-08-0409.
   PubMed Web of Science ®Google Scholar
• Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5(1):102–114. doi:10.2174/1874467211205010102.
   PubMedGoogle Scholar
• Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13(7):2038–2045. doi:10.1158/1078-0432.CCR-06-2149.
   PubMed Web of Science ®Google Scholar
• Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 2012;122(1):253–266. doi:10.1172/JCI59334.
   PubMed Web of Science ®Google Scholar
• Wharton SB, McNelis U, Bell HS, Whittle IR. Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol Appl Neurobiol. 2000;26(6):528–535. doi:10.1046/j.0305-1846.2000.00288.x.
   PubMed Web of Science ®Google Scholar
• Bandey I, Chiou SH, Huang AP, Tsai JC, Tu PH. Progranulin promotes temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness. Oncogene. 2015;34(14):1853–1864. doi:10.1038/onc.2014.92.
   PubMed Web of Science ®Google Scholar
• Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer. 2014;14:151. doi:10.1186/1471-2407-14-151.
   PubMed Web of Science ®Google Scholar
• Yang B, Fu X, Hao J, Sun J, Li Z, Li H, Xu H. PAXX participates in base excision repair via interacting with Pol β and contributes to TMZ resistance in glioma cells. J Mol Neurosci. 2018;66(2):214–221. doi:10.1007/s12031-018-1157-4.
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001;42(7):1007–1017.
   PubMed Web of Science ®Google Scholar
• van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der Maas M, Weijers GW, et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica. 2003;88(2):134–147.
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat. 2005;8(1–2):15–26. doi:10.1016/j.drup.2005.02.002.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Gottesman MM. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol. 2011;12(4):686–692. doi:10.2174/138920111795163931.
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591–602. doi:10.1038/nrn1728.
   PubMed Web of Science ®Google Scholar
• Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, et al. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int J Cancer. 1994;58(6):860–864. doi:10.1002/ijc.2910580619.
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86–98. doi:10.1602/neurorx.2.1.86.
   PubMedGoogle Scholar
• Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76(1):22–76. doi:10.1016/j.pneurobio.2005.04.006.
   PubMed Web of Science ®Google Scholar
• Warrier S, Pavanram P, Raina D, Arvind M. Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int. 2012;36(12):1137–1143. doi:10.1042/CBI20110539.
   PubMed Web of Science ®Google Scholar
• Xu ZY, Wang K, Li XQ, Chen S, Deng JM, Cheng Y, Wang ZG. The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells. Ultrasonics. 2013;53(1):232–238. doi:10.1016/j.ultras.2012.06.005.
   PubMed Web of Science ®Google Scholar
• Li WQ, Li YM, Tao BB, Lu YC, Hu GH, Liu HM, et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit. 2010;16(10):HY27–HY30.
   PubMed Web of Science ®Google Scholar
• Martin V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013;108(10):2005–2012. doi:10.1038/bjc.2013.188.
   PubMed Web of Science ®Google Scholar
• Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, et al. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. 2009;135(10):1369–1376. doi:10.1007/s00432-009-0578-4.
   PubMed Web of Science ®Google Scholar
• Chen L, Shi L, Wang W, Zhou Y. ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin. Oncotarget. 2017;8(26):43237–43247. doi:10.18632/oncotarget.18018.
   PubMedGoogle Scholar
• Torres A, Arriagada V, Erices JI, Toro MLA, Rocha JD, Niechi I, et al. FK506 attenuates the MRP1-mediated chemoresistant phenotype in glioblastoma stem-like cells. Int J Mol Sci. 2018;19(9):2697.
   Web of Science ®Google Scholar
• Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 2015;367(1):69–75. doi:10.1016/j.canlet.2015.07.013.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–760. doi:10.1038/nature05236.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477. doi:10.1016/j.cell.2013.09.034.
   PubMed Web of Science ®Google Scholar
• Han J, Puri RK. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol. 2018;136(3):463–474. doi:10.1007/s11060-017-2680-9.
   PubMed Web of Science ®Google Scholar
• Korber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, et al. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell. 2019;35(4):692–704.e12. doi:10.1016/j.ccell.2019.02.007.
   PubMed Web of Science ®Google Scholar
• Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785):112–120. doi:10.1038/s41586-019-1775-1.
   PubMed Web of Science ®Google Scholar
• Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, et al. Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study. J Clin Oncol. 2020;38(1):81–99. doi:10.1200/JCO.19.00367.
   PubMed Web of Science ®Google Scholar
• de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, et al. A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence. Cell Rep. 2018;23(2):637–651. doi:10.1016/j.celrep.2018.03.107.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Gittleman H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neurooncol Adv. 2019;1(1):vdz007. doi:10.1093/noajnl/vdz007.
   PubMedGoogle Scholar
• Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi:10.1016/j.ccr.2009.12.020.
   PubMed Web of Science ®Google Scholar
• Li L, Huang Y, Gao Y, Shi T, Xu Y, Li H, et al. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence. BMC Cancer. 2018;18(1):1215. doi:10.1186/s12885-018-5056-4.
   PubMedGoogle Scholar
• Rabe M, Dumont S, Alvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, et al. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis. 2020;11(1):19. doi:10.1038/s41419-019-2200-2.
   PubMed Web of Science ®Google Scholar
• Wickstrom M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjornsson B, et al. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun. 2015;6:8904. doi:10.1038/ncomms9904.
   PubMed Web of Science ®Google Scholar
• Jiapaer S, Furuta T, Dong Y, Kitabayashi T, Sabit H, Zhang J, et al. Identification of 2-fluoropalmitic acid as a potential therapeutic agent against glioblastoma. Curr Pharm Des. 2020;26(36):4675–4684.
   PubMed Web of Science ®Google Scholar
• Li Z, Xia Y, Bu X, Yang D, Yuan Y, Guo X, et al. Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU. Oncol Lett. 2018;15(6):9877–9883. doi:10.3892/ol.2018.8551.
   PubMed Web of Science ®Google Scholar
• Shen D, Guo CC, Wang J, Qiu ZK, Sai K, Yang QY, et al. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. Oncol Rep. 2015;34(5):2715–2721. doi:10.3892/or.2015.4232.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Y, Sun S, Zhang G, Jiang K, Sun P, et al. Bufalin induces apoptosis and improves the sensitivity of human glioma stem-like cells to temozolamide. Oncol Res. 2019;27(4):475–486. doi:10.3727/096504018X15270916676926.
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101(39):14228–14233. doi:10.1073/pnas.0400067101.
   PubMed Web of Science ®Google Scholar
• Gong W, Wang Z, Wan Y, Shi L, Zhou Y. Downregulation of ABCG2 protein inhibits migration and invasion in U251 glioma stem cells. Neuroreport. 2014;25(8):625–632. doi:10.1097/WNR.0000000000000161.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang Z, Sun G, Wan Y, Guo J, Fu X. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med. 2014;16(2):517–528. doi:10.1007/s12017-014-8305-y.
   PubMed Web of Science ®Google Scholar
• Emery IF, Gopalan A, Wood S, Chow KH, Battelli C, George J, et al. Expression and function of ABCG2 and XIAP in glioblastomas. J Neurooncol. 2017;133(1):47–57. doi:10.1007/s11060-017-2422-z.
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo Q, Zhang H, Li GH, Feng S, Yu XZ, et al. Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133(+) stem cells. Exp Ther Med. 2015;10(4):1317–1323. doi:10.3892/etm.2015.2675.
   PubMed Web of Science ®Google Scholar
• Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, et al. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer. 2015;14:189. doi:10.1186/s12943-015-0459-1.
   PubMed Web of Science ®Google Scholar
• Imai Y, Yamagishi H, Ono Y, Ueda Y. Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin Transl Med. 2012;1(1):24. doi:10.1186/2001-1326-1-24.
   PubMedGoogle Scholar
• Zhang Y, Wang SX, Ma JW, Li HY, Ye JC, Xie SM, et al. EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J Neurooncol. 2015;121(1):41–52. doi:10.1007/s11060-014-1604-1.
   PubMed Web of Science ®Google Scholar
• Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, et al. Carbonic anhydrase XII inhibitors overcome P-glycoprotein-mediated resistance to temozolomide in glioblastoma. Mol Cancer Ther. 2018;17(12):2598–2609. doi:10.1158/1535-7163.MCT-18-0533.
   PubMed Web of Science ®Google Scholar
• Qi SG, Quan LQ, Cui XY, Li HM, Zhao XD, Li RT. A natural compound obtained from Valeriana jatamansi selectively inhibits glioma stem cells. Oncol Lett. 2020;19(2):1384–1392. doi:10.3892/ol.2019.11239.
   PubMed Web of Science ®Google Scholar
• Marin-Ramos NI, Perez-Hernandez M, Tam A, Swenson SD, Cho HY, Thein TZ, et al. Inhibition of motility by NEO100 through the calpain-1/RhoA pathway. J Neurosurg. 2019;133(4):1–12.
   Web of Science ®Google Scholar
• Wang Z, Liang P, He X, Wu B, Liu Q, Xu Z, et al. Etoposide loaded layered double hydroxide nanoparticles reversing chemoresistance and eradicating human glioma stem cells in vitro and in vivo. Nanoscale. 2018;10(27):13106–13121. doi:10.1039/c8nr02708k.
   PubMed Web of Science ®Google Scholar
• Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, et al. Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. Oncotarget. 2017;8(68):112662–112674. doi:10.18632/oncotarget.22637.
   PubMedGoogle Scholar
• Bijangi-Vishehsaraei K, Reza Saadatzadeh M, Wang H, Nguyen A, Kamocka MM, Cai W, et al. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. J Neurosurg. 2017;127(6):1219–1230. doi:10.3171/2016.8.JNS161197.
   PubMed Web of Science ®Google Scholar
• Kim BH, Lee H, Park CG, Jeong AJ, Lee SH, Noh KH, et al. STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model. Cells. 2020;9(3):722. doi:10.3390/cells9030722.
   PubMed Web of Science ®Google Scholar
• Luwor R, Morokoff AP, Amiridis S, D'Abaco G, Paradiso L, Stylli SS, et al. Targeting glioma stem cells by functional inhibition of dynamin 2: a novel treatment strategy for glioblastoma. Cancer Invest. 2019;37(3):144–155. doi:10.1080/07357907.2019.1582060.
   PubMed Web of Science ®Google Scholar
• Kuramoto K, Yamamoto M, Suzuki S, Sanomachi T, Togashi K, Seino S, et al. Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells. FEBS J. 2020;287(10):2023–2036. doi:10.1111/febs.15187.
   PubMed Web of Science ®Google Scholar
• Wen YT, Wu AT, Bamodu OA, Wei L, Lin CM, Yen Y, et al. A novel multi-target small molecule, LCC-09, inhibits stemness and therapy-resistant phenotypes of glioblastoma cells by increasing miR-34a and deregulating the DRD4/Akt/mTOR signaling axis. Cancers. 2019;11(10):1442. doi:10.3390/cancers11101442.
   Web of Science ®Google Scholar
• Kitabayashi T, Dong Y, Furuta T, Sabit H, Jiapaer S, Zhang J, et al. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Sci Rep. 2019;9(1):10049. doi:10.1038/s41598-019-46454-8.
   PubMedGoogle Scholar
• Marín-Ramos NI, Thein TZ, Cho H-Y, Swenson SD, Wang W, Schönthal AH, et al. Hofman FM: NEO212 inhibits migration and invasion of glioma stem cells. Mol Cancer Ther. 2018;17(3):625–637. doi:10.1158/1535-7163.MCT-17-0591.
   PubMed Web of Science ®Google Scholar
• Doan P, Musa A, Murugesan A, Sipila V, Candeias NR, Emmert-Streib F, et al. Glioblastoma multiforme stem cell cycle arrest by alkylaminophenol through the modulation of EGFR and CSC signaling pathways. Cells. 2020;9(3):681. doi:10.3390/cells9030681.
   Web of Science ®Google Scholar
• Daniele S, Sestito S, Pietrobono D, Giacomelli C, Chiellini G, Di Maio D, et al. Dual inhibition of PDK1 and aurora kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells. ACS Chem Neurosci. 2017;8(1):100–114. doi:10.1021/acschemneuro.6b00251.
   PubMed Web of Science ®Google Scholar
• Rampazzo E, Dettin M, Maule F, Scabello A, Calvanese L, D'Auria G, et al. A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation. Biochim Biophys Acta. 2017;1861(9):2282–2292. doi:10.1016/j.bbagen.2017.07.001.
   Web of Science ®Google Scholar
• Allani SK, Weissbach H, Lopez Toledano MA. Sulindac induces differentiation of glioblastoma stem cells making them more sensitive to oxidative stress. Neoplasma. 2018;65(3):376–388. doi:10.4149/neo_2018_170404N245.
   PubMed Web of Science ®Google Scholar
• Lin Y, Sun H, Dang Y, Li Z. Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells. Oncol Rep. 2018;39(2):687–694. doi:10.3892/or.2017.6154.
   PubMed Web of Science ®Google Scholar
• Bielecka-Wajdman AM, Lesiak M, Ludyga T, Sieroń A, Obuchowicz E. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme. Cancer Chemother Pharmacol. 2017;79(6):1249–1256. doi:10.1007/s00280-017-3329-2.
   PubMed Web of Science ®Google Scholar
• Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, et al. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets. 2016;20(4):393–405. doi:10.1517/14728222.2016.1151002.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang H, Sun Q, Ji X, Zhu L, Cong Z, et al. Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer. 2013;13:380. doi:10.1186/1471-2407-13-380.
   PubMed Web of Science ®Google Scholar
• Cong ZX, Wang HD, Zhou Y, Wang JW, Pan H, Zhang DD, et al. Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma a cells. J Neurooncol. 2014;116(1):41–48. doi:10.1007/s11060-013-1260-x.
   PubMed Web of Science ®Google Scholar
• Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, et al. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 2015;29(7):732–745. doi:10.1101/gad.257394.114.
   PubMed Web of Science ®Google Scholar
• Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr., Hemmings BA, et al. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLOS One. 2009;4(10):e7443: doi:10.1371/journal.pone.0007443.
   PubMed Web of Science ®Google Scholar
• Zhu TZ, Li XM, Luo LH, Song ZQ, Gao X, Li ZQ, et al. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells . Int J Oncol. 2014;45(2):699–709. doi:10.3892/ijo.2014.2448.
   PubMed Web of Science ®Google Scholar
• Megias J, Martinez A, San-Miguel T, Gil-Benso R, Munoz-Hidalgo L, Albert-Bellver D, et al. Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide. Invest New Drugs. 2020;38(2):299–310. doi:10.1007/s10637-019-00788-2.
   PubMed Web of Science ®Google Scholar
• Arrizabalaga O, Moreno-Cugnon L, Auzmendi-Iriarte J, Aldaz P, Ibanez de Caceres I, Garros-Regulez L, et al. High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response. Oncogenesis. 2017;6(12):401. doi:10.1038/s41389-017-0003-9.
   PubMedGoogle Scholar
• Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 2014;21(7):1119–1131. doi:10.1038/cdd.2014.31.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wu T, Liu AY, Ouyang G. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget. 2015;6(37):39550–39563. doi:10.18632/oncotarget.6098.
   PubMedGoogle Scholar
• Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102(5):789–795. doi:10.1038/sj.bjc.6605551.
   PubMed Web of Science ®Google Scholar
• Ahmed EM, Bandopadhyay G, Coyle B, Grabowska A. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell Oncol. 2018;41(3):319–328. doi:10.1007/s13402-018-0374-8.
   Web of Science ®Google Scholar
• Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012;1(4):322–332. doi:10.5966/sctm.2011-0035.
   PubMed Web of Science ®Google Scholar
• Lee DH, Cheul Oh S, Giles AJ, Jung J, Gilbert MR, Park DM. Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1α in human glioma stem cells. Oncotarget. 2017;8(25):40233–40245. doi:10.18632/oncotarget.16714.
   PubMedGoogle Scholar
• Nusblat LM, Tanna S, Roth CM. Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype. Cancer Drug Resist. 2020;3(2):199–208. doi:10.20517/cdr.2019.96.
   PubMedGoogle Scholar
• Li Q, Qiao G, Ma J, Li Y. Downregulation of VEGF expression attenuates malignant biological behavior of C6 glioma stem cells. Int J Oncol. 2014;44(5):1581–1588. doi:10.3892/ijo.2014.2331.
   PubMed Web of Science ®Google Scholar
• Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, et al. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res. 2017;36(1):106. doi:10.1186/s13046-017-0577-2.
   PubMedGoogle Scholar
• Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015;20(2):166–175. doi:10.1634/theoncologist.2014-0330.
   PubMed Web of Science ®Google Scholar
• Carter TC, Medina-Flores R, Lawler BE. Glioblastoma treatment with temozolomide and bevacizumab and overall survival in a rural tertiary healthcare practice. Biomed Res Int. 2018;2018:1–10. doi:10.1155/2018/6204676.
   Web of Science ®Google Scholar
• Ramezani S, Vousooghi N, Kapourchali FR, Hadjighasem M, Hayat P, Amini N, Joghataei MT. Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells. Life Sci. 2017;173:11–19. doi:10.1016/j.lfs.2017.02.005.
   PubMed Web of Science ®Google Scholar
• Hoang-Minh LB, Deleyrolle LP, Nakamura NS, Parker AK, Martuscello RT, Reynolds BA, Sarkisian MR. PCM1 depletion inhibits glioblastoma cell ciliogenesis and increases cell death and sensitivity to temozolomide. Transl Oncol. 2016;9(5):392–402. doi:10.1016/j.tranon.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Wu W, Wu Y, Mayer K, von Rosenstiel C, Schecker J, Baur S, et al. Lipid peroxidation plays an important role in chemotherapeutic effects of temozolomide and the development of therapy resistance in human glioblastoma. Transl Oncol. 2020;13(3):100748. doi:10.1016/j.tranon.2020.100748.
   PubMed Web of Science ®Google Scholar
• MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, et al. Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells. Cell Rep. 2019;27(3):971–986.e9. doi:10.1016/j.celrep.2019.03.047.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017;266:17–26. doi:10.1016/j.jconrel.2017.09.012.
   PubMed Web of Science ®Google Scholar
• Akasaki Y, Kikuchi T, Homma S, Koido S, Ohkusa T, Tasaki T, et al. Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. Cancer Immunol Immunother. 2016;65(12):1499–1509. doi:10.1007/s00262-016-1905-7.
   PubMed Web of Science ®Google Scholar
• Enriquez Perez J, Kopecky J, Visse E, Darabi A, Siesjo P. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. BMC Cancer. 2020;20(1):7. doi:10.1186/s12885-019-6502-7.
   PubMed Web of Science ®Google Scholar
• Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol. 2010;225(1–2):22–33. doi:10.1016/j.jneuroim.2010.04.003.
   PubMed Web of Science ®Google Scholar
• Heynckes S, Gaebelein A, Haaker G, Grauvogel J, Franco P, Mader I, et al. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget. 2017;8(43):74170–74177. doi:10.18632/oncotarget.18819.
   PubMedGoogle Scholar
• Saha D, Rabkin SD, Martuza RL. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020;8(1):e000345. doi:10.1136/jitc-2019-000345.
   PubMed Web of Science ®Google Scholar
• Bian S, Repic M, Guo Z, Kavirayani A, Burkard T, Bagley JA, et al. Genetically engineered cerebral organoids model brain tumor formation. Nat Methods. 2018;15(8):631–639. doi:10.1038/s41592-018-0070-7.
   PubMed Web of Science ®Google Scholar
• Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188–204.e122. doi:10.1016/j.cell.2019.11.036.
   PubMed Web of Science ®Google Scholar
• Hwang JW, Loisel-Duwattez J, Desterke C, Latsis T, Pagliaro S, Griscelli F, et al. A novel neuronal organoid model mimicking glioblastoma (GBM) features from induced pluripotent stem cells (iPSC). Biochim Biophys Acta Gen Subj. 2020;1864(4):129540. doi:10.1016/j.bbagen.2020.129540.
   PubMed Web of Science ®Google Scholar
• Menegotto PR, da Costa Lopez PL, Souza BK, de Farias CB, Filippi-Chiela EC, Vieira IA, et al. Gastrin-releasing peptide receptor knockdown induces senescence in glioblastoma cells. Mol Neurobiol. 2017;54(2):888–894. doi:10.1007/s12035-016-9696-6.
   PubMed Web of Science ®Google Scholar
• de Oliveira MS, Cechim G, Braganhol E, Santos DG, Meurer L, de Castro CG, Jr, et al. Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol. 2009;93(2):191–201. doi:10.1007/s11060-008-9775-2.
   PubMed Web of Science ®Google Scholar
• Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835–849 e821. doi:10.1016/j.cell.2019.06.024.
   PubMed Web of Science ®Google Scholar
• Dirkse A, Golebiewska A, Buder T, Nazarov PV, Muller A, Poovathingal S, et al. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun. 2019;10(1):1787. doi:10.1038/s41467-019-09853-z.
   PubMedGoogle Scholar
• Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell. 2017;20(2):233–246.e7. doi:10.1016/j.stem.2016.11.003.
   PubMed Web of Science ®Google Scholar
• Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci. 2019;20(11):2746.
   Web of Science ®Google Scholar
• Bhaduri A, Di Lullo E, Jung D, Muller S, Crouch EE, Espinosa CS, et al. Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell. 2020;26(1):48–63.e6. doi:10.1016/j.stem.2019.11.015.
   PubMed Web of Science ®Google Scholar
• Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA. 2015;112(3):851–856. doi:10.1073/pnas.1320611111.
   PubMed Web of Science ®Google Scholar